ID 83940
Author
Takahashi, Masaaki Department of Pharmacy National Hospital Organization Nagoya Medical Center|Clinical Research Center, National Hospital Organization Nagoya Medical Center
Hirano, Atsushi Department of Pharmacy National Hospital Organization Nagoya Medical Center|Clinical Research Center, National Hospital Organization Nagoya Medical Center
Okubo, Nami Department of Pharmacy National Hospital Organization Nagoya Medical Center
Kinoshita, Eri Department of Pharmacy National Hospital Organization Nagoya Medical Center
Nomura, Toshiharu Department of Pharmacy National Hospital Organization Nagoya Medical Center
Kaneda, Tsuguhiro College of Pharmacy, Kinjo Gakuin University
Keywords
maraviroc
CCR5 antagonist
HIV-1
LC-MS
therapeutic drug monitoring
Content Type
Journal Article
Description
Maraviroc is an orally available antagonist of the CCR5 chemokine receptor,
which acts as a human immunodeficiency virus type 1 (HIV-1) coreceptor. Binding of maraviroc
to this receptor blocks HIV-1 attachment to the coreceptor and prevents HIV-1
from entering host cells.Maraviroc does not require intracellular processing to exert
this activity. Drug interaction studies have shown changes in maraviroc exposure when
given with other anti-HIV medications, and thus quantification of maraviroc in human
plasma is important to manage drug interactions and to evaluate the relationship between
plasma concentrations and treatment response. We developed a conventional LCMS
method for determining plasma maraviroc concentrations, validated by estimating
precision and accuracy for inter- and intraday analysis in the concentration range of
0.011-2.188g/ml. The calibration curve was linear within this range. The average accuracy
ranged from 92.7% to 99.7%, while the relative standard deviations of both interand
intraday assays were less than 7.1%. Recovery of maraviroc exceeded 86.7%. Our LCMS
method provides a conventional, accurate and precise way to determine the maraviroc
concentration in human plasma. This method enables dose adjustment based on monitoring
plasma maraviroc concentrations and permits management of drug interactions
and toxicity.
Journal Title
The journal of medical investigation : JMI
ISSN
13431420
NCID
AA11166929
Volume
57
Issue
3-4
Start Page
245
End Page
250
Sort Key
245
Published Date
2010-08
Remark
The journal of medical investigation : http://medical.med.tokushima-u.ac.jp/jmi/index.html
FullText File
language
eng